<SEC-DOCUMENT>0001493152-22-025297.txt : 20220907
<SEC-HEADER>0001493152-22-025297.hdr.sgml : 20220907
<ACCEPTANCE-DATETIME>20220907204802
ACCESSION NUMBER:		0001493152-22-025297
CONFORMED SUBMISSION TYPE:	3
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20220829
FILED AS OF DATE:		20220907
DATE AS OF CHANGE:		20220907

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Richards Steven M
		CENTRAL INDEX KEY:			0001945980

	FILING VALUES:
		FORM TYPE:		3
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41488
		FILM NUMBER:		221232340

	MAIL ADDRESS:	
		STREET 1:		SHUTTLE PHARMACEUTICALS HOLDINGS, INC.
		STREET 2:		ONE RESEARCH COURT, SUITE 450
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Shuttle Pharmaceuticals Holdings, Inc.
		CENTRAL INDEX KEY:			0001757499
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		ONE RESEARCH COURT
		STREET 2:		SUITE 450
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
		BUSINESS PHONE:		2404034212

	MAIL ADDRESS:	
		STREET 1:		ONE RESEARCH COURT
		STREET 2:		SUITE 450
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
</SEC-HEADER>
<DOCUMENT>
<TYPE>3
<SEQUENCE>1
<FILENAME>ownership.xml
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0206</schemaVersion>

    <documentType>3</documentType>

    <periodOfReport>2022-08-29</periodOfReport>

    <noSecuritiesOwned>0</noSecuritiesOwned>

    <issuer>
        <issuerCik>0001757499</issuerCik>
        <issuerName>Shuttle Pharmaceuticals Holdings, Inc.</issuerName>
        <issuerTradingSymbol>SHPH</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001945980</rptOwnerCik>
            <rptOwnerName>Richards Steven M</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O SHUTTLE PHARMACEUTICALS HOLDINGS</rptOwnerStreet1>
            <rptOwnerStreet2>ONE RESEARCH COURT, SUITE 450</rptOwnerStreet2>
            <rptOwnerCity>ROCKVILLE</rptOwnerCity>
            <rptOwnerState>MD</rptOwnerState>
            <rptOwnerZipCode>20850</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>1</isDirector>
            <isOfficer>0</isOfficer>
            <isTenPercentOwner>0</isTenPercentOwner>
            <isOther>0</isOther>
            <officerTitle></officerTitle>
            <otherText></otherText>
        </reportingOwnerRelationship>
    </reportingOwner>

    <nonDerivativeTable>
        <nonDerivativeHolding>
            <securityTitle>
                <value>COMMON STOCK</value>
            </securityTitle>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>2702</value>
                    <footnoteId id="F1"/>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeHolding>
    </nonDerivativeTable>

    <footnotes>
        <footnote id="F1">The undersigned became a Reporting Person subject to Section 16 reporting on August 29, 2022 at the time Shuttle Pharmaceuticals Holdings, Inc (&quot;Company&quot;) completed its initial public offering (&quot;IPO&quot;). At the time of the IPO, the Reporting Person was the beneficial owner of 2,702 shares of common stock of the Company, consisting of 2,702 restricted stock units, all of which have fully vested.</footnote>
    </footnotes>

    <ownerSignature>
        <signatureName>/s/ Steven M Richards</signatureName>
        <signatureDate>2022-09-07</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
